Sampath Wijesinghe, PA
Medical · Sanger, CANPI 1912216581
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (34.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Gilead at 50.5% of the total. 2025 is the largest year on record at $12,366, more than ten times the $31 reported in 2021. Among medical clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 183 payments — averaging $112.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$10K
- Viiv Healthcare Company$6K
- Modernatx, Inc.$1K
- AbbVie$503
- AstraZeneca$442
- Lilly USA, LLC$281
- plus $2K from 29 others
What the payments were for
- Consulting fees$4,89524%
- Speaking & faculty fees$7,17835%
- Travel & lodging$3,47417%
- Food & beverage$5,08925%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 31 | $10,431 |
| Viiv Healthcare Company | 28 | $5,789 |
| Modernatx, Inc. | 1 | $1,295 |
| AbbVie | 30 | $503 |
| AstraZeneca | 5 | $442 |
| Lilly USA, LLC | 14 | $281 |
| Novo Nordisk | 11 | $214 |
| Amgen | 9 | $169 |
| Corcept Therapeutics | 2 | $155 |
| Boston Scientific | 1 | $142 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $123 |
| Axsome Therapeutics, Inc. | 4 | $118 |
| Abiomed | 4 | $108 |
| Xeris Pharmaceuticals, Inc. | 4 | $75 |
| Pfizer | 4 | $74 |
| Treace Medical Concepts, Inc. | 1 | $72 |
| Bayer | 4 | $71 |
| GSK | 4 | $69 |
| Boehringer Ingelheim | 3 | $53 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Dynavax Technologies Corporation | 2 | $50 |
| Merck | 2 | $46 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Aimmune Therapeutics, Inc. | 2 | $32 |
| Antares Pharma, Inc. | 1 | $30 |
| Daiichi Sankyo Inc. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $22 |
| Tolmar, Inc. | 1 | $20 |
| Verity Pharmaceuticals Inc. | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Dexcom, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Descovy$6,596
- DOVATO$3,911
- Yeztugo$2,764
- Moderna Covid-19 Vaccine$1,295
- AIRSUPRA$244
- GENERAL - THERAPIES$142
- Epclusa$125
- BREZTRI$125
- Korlym$124
- XIFAXAN$123
How this compares
$20,635 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 23 | $31,651 |
| SynjardyEmpagliflozin/Metformin Hcl | 26 | $25,910 |
| JanuviaSitagliptin Phosphate | 11 | $10,697 |
| EliquisApixaban | 14 | $9,919 |
| Anagrelide Hcl | 12 | $4,694 |
| Atorvastatin Calcium | 177 | $1,749 |
| Gabapentin | 62 | $1,223 |
| Metoprolol Succinate | 54 | $1,096 |
| Levothyroxine Sodium | 75 | $1,062 |
| Losartan Potassium | 77 | $914 |
| Amlodipine Besylate | 112 | $839 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $774 |
| Lisinopril | 96 | $732 |
| Sertraline Hcl | 63 | $722 |
| Tamsulosin Hcl | 40 | $721 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy | $53 | $57,56149 claims |
| MerckJanuvia | $46 | $10,69711 claims |
| PfizerEliquis | $74 | $9,91914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 medical providers in California.
Other medical in Sanger
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- David DoriguzziLancaster$166K
- Deirdre MoxleyFullerton$149K
- Linda RankLadera Ranch$105K
- Cheryl KyinnSan Diego$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.